Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

33%

Ph not_applicable

33%

Ph early_phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

1(33.3%)

Phase 1Safety & dosage

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Detailed Status

Completed2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Early Phase 11 (33.3%)

Phase 11 (33.3%)

N/A1 (33.3%)

Trials by Status

completed267%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

completedearly_phase_1

Noninvasive Markers of Functional Nausea in Children

NCT03593811

recruitingphase_1

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637

completednot_applicable

Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis

NCT02099214

Clinical Trials (3)

Showing 3 of 3 trials

NCT03593811Early Phase 1

Noninvasive Markers of Functional Nausea in Children

Completed

NCT03952637Phase 1

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Recruiting

NCT02099214Not Applicable

Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis

Completed

All 3 trials loaded

Drug Details

Intervention Type: DIAGNOSTIC TEST
Total Trials: 3